AlloVir appoints Derek Adams to board; Ansbert Gadicke retires

Kalaris Therapeutics, Inc.

Derek Adams, Ph.D. appointed to Board effective March 1, 2023, filling vacancy from Ansbert Gadicke's retirement.
Dr. Adams brings over 20 years of experience in manufacturing biologic and gene therapies; currently CEO of Stellular Bio.
Ansbert Gadicke, M.D. retires from board effective February 28, 2023; no disagreement with company.
AlloVir is a late-clinical stage allogeneic T cell immunotherapy company with three ongoing Phase 3 studies for posoleucel.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ansbert Gadicke

Director

KLRS · Kalaris Therapeutics, Inc.

Effective: 2023-02-28
Successor: Derek Adams
Filed: February 23, 2023, 6:59 PM ET

Ansbert Gadicke, M.D. notified the Board that he will be retiring from the Board effective February 28, 2023.

Appointed

Derek Adams

Director

KLRS · Kalaris Therapeutics, Inc.

Effective: 2023-03-01
Filed: February 23, 2023, 6:59 PM ET

the Board appointed Derek Adams, Ph.D. to the Board, effective March 1, 2023, to fill a newly created vacancy resulting from the retirement of Ansbert Gadicke, M.D.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ansbert Gadicke retired as Director at Kalaris Therapeutics, Inc..

Action: retired
Role: Director

Exact text from the filing

Ansbert Gadicke, M.D. notified the Board that he will be retiring from the Board effective February 28, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Derek Adams was appointed as Director at Kalaris Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Derek Adams, Ph.D. to the Board, effective March 1, 2023, to fill a newly created vacancy resulting from the retirement of Ansbert Gadicke, M.D.

View on SEC.gov

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-046651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.